Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or After a Trastuzumab-Containing Regimen

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2021
This article has no abstract
Epistemonikos ID: 49fe3c58068733eb493e42445ed7f9dd4bc03716
First added on: Apr 11, 2025